Leerink Partnrs Estimates Arvinas’ Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Arvinas in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.50) per share for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.89) EPS and FY2026 earnings at ($3.53) EPS.

ARVN has been the topic of a number of other reports. Oppenheimer lowered their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. Barclays reduced their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Guggenheim reissued a “buy” rating on shares of Arvinas in a report on Thursday, December 12th. Finally, BTIG Research initiated coverage on Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price for the company. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $61.45.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $18.97 on Monday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -4.06 and a beta of 1.88. The firm’s 50 day simple moving average is $19.46 and its 200-day simple moving average is $23.44. Arvinas has a 12 month low of $16.61 and a 12 month high of $53.08.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB boosted its position in Arvinas by 17.4% during the third quarter. Handelsbanken Fonder AB now owns 19,525 shares of the company’s stock worth $481,000 after acquiring an additional 2,900 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after purchasing an additional 1,798 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Arvinas in the third quarter valued at approximately $39,000. Assenagon Asset Management S.A. acquired a new stake in shares of Arvinas in the third quarter valued at approximately $3,442,000. Finally, E. Ohman J or Asset Management AB lifted its position in Arvinas by 20.1% during the third quarter. E. Ohman J or Asset Management AB now owns 29,830 shares of the company’s stock worth $735,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.